Weight Gain and Metabolic Syndrome in Human Immunodeficiency Virus Patients

Citations

WEB OF SCIENCE

19
Citations

SCOPUS

22

초록

While human immunodeficiency virus (HIV)-associated wasting has declined with significant advances in antiretroviral therapy (ART), weight gain and metabolic syndrome (MetS) are now becoming a problem for people living with HIV (PLWH) worldwide. The development of a new and more effective ART regimen has increased viral suppression and improved immunologic function recovery, leading to the extension of the lifespan of PLWH. It has recently been reported as one of the significant factors associated with weight gain, obesity, and long-term metabolic consequences in PLWH. This article reviewed the epidemiology of overweight and MetS among PLWH and the known risk factors for weight gain and its major comorbidities, such as dyslipidemia, diabetes mellitus, cardiovascular diseases, neurocognitive disorders, and liver diseases, in PLWH. In addition, reports on the pharmacological and surgical management of overweight and obesity in PLWH has been briefly summarized.

키워드

HIV; Metabolic syndrome; Weight gain; Obesity; Antiretroviral therapy; Highly active; TENOFOVIR DISOPROXIL FUMARATE; INITIATING ANTIRETROVIRAL THERAPY; HIV-INFECTED PATIENTS; FATTY LIVER-DISEASE; BARIATRIC SURGERY; CARDIOVASCULAR-DISEASE; BODY-COMPOSITION; RISK-FACTORS; OBESITY; EMTRICITABINE
제목
Weight Gain and Metabolic Syndrome in Human Immunodeficiency Virus Patients
저자
Chang, Hyun-Ha
DOI
10.3947/ic.2022.0061
발행일
2022-06
유형
Review
저널명
Infection and Chemotherapy
권
54
호
2
페이지
220 ~ 235